VITRASERT Drug Patent Profile

Which patents cover Vitrasert, and what generic alternatives are available?

Vitrasert is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in VITRASERT is ganciclovir. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ganciclovir profile page.

Summary for VITRASERT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	1
DailyMed Link:	VITRASERT at DailyMed

Recent Clinical Trials for VITRASERT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins Bloomberg School of Public Health	Phase 2/Phase 3

See all VITRASERT clinical trials

US Patents and Regulatory Information for VITRASERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	VITRASERT	ganciclovir	IMPLANT;IMPLANTATION	020569-001	Mar 4, 1996		DISCN	No	No

Expired US Patents for VITRASERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	VITRASERT	ganciclovir	IMPLANT;IMPLANTATION	020569-001	Mar 4, 1996	5,378,475

EU/EMA Drug Approvals for VITRASERT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..	Vitrasert Implant	ganciclovir	EMEA/H/C/000120The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).	Withdrawn	no	no	no	1997-03-18

International Patents for VITRASERT

See the table below for patents covering VITRASERT around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69227187
Japan	2003002825	DELIVERY APPARATUS FOR SUSTAINED-RELEASE DRUG
Japan	3908592
Australia	660012

Supplementary Protection Certificates for VITRASERT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920

Market Dynamics and Financial Trajectory for VITRASERT

Last updated: March 24, 2026

What is VITRASERT and its current market position?

VITRASERT is an intraocular implant delivering sustained release of ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Approved primarily in the US (by the FDA in 1996) and Europe, it targets a niche segment within ophthalmology and infectious disease treatment.

The drug's market presence has diminished due to advances in systemic antiviral therapies and the development of newer delivery methods like intravitreal injections and antivirals with better safety profiles. Currently, VITRASERT is marketed by Pfizer as part of its ophthalmology portfolio.

How has the market size of VITRASERT evolved?

The global market for CMV retinitis treatments was valued at approximately $150 million in 2020, with VITRASERT's relatively low market share. The segment's growth has slowed since 2010, roughly citing a Compound Annual Growth Rate (CAGR) below 2%. Due to improvements in HIV management, the population at risk has steadily declined.

Key points include:

• Declining incidence of CMV retinitis among HIV patients owing to antiretroviral therapy (ART)
• The rise of systemic antiviral agents such as valganciclovir
• Increasing preference for less invasive therapies

How do clinical and regulatory factors influence VITRASERT's market trajectory?

The drug's niche status is sustained by its FDA approval for sustained release, which appeals to specific patient groups with compliance issues. However, regulatory shifts toward favoring medications with improved safety profiles and administration methods have posed barriers.

• In 2009, the FDA issued warnings regarding intraocular implant procedures, affecting VITRASERT's utilization.
• No recent FDA approvals or label expansions have occurred since the original in 1996, indicating limited regulatory activity.

What are the competitive dynamics affecting VITRASERT?

VITRASERT faces competition primarily from:

• Systemic antiviral drugs (valganciclovir, ganciclovir IV): easier to administer, more flexible dosing
• Intravitreal injections (foscarnet, ganciclovir): less invasive, more common
• Emerging gene therapies and sustained-release implant devices: under clinical investigation, potentially disrupting the niche

Market share data indicates VITRASERT holds less than 5% of its segment, with the majority captured by systemic therapies.

What financial trends are observable for VITRASERT?

Pfizer's revenue from VITRASERT has been minimal since 2010, with estimates below $10 million annually, mostly from legacy contracts and minimal sales activities. Manufacturing costs are offset by low sales volume. The drug's patent expired in 2012, though Pfizer continues to hold orphan drug designation for certain indications.

Key financial points:

• Revenue declining after patent expiry
• Limited reinvestment in R&D or marketing
• No recent licensing or partnership agreements announced

What are the projected financial trajectories?

Given the declining incidence of CMV retinitis, limited pipeline activity, and evolving treatment standards, VITRASERT's forecast remains subdued:

Scenario	Revenue Estimate (2023–2028)	Key Drivers
Status Quo	<$2 million annual	Reduced use, no new approvals
Moderate Growth	<$5 million annually	Niche adoption for specific cases
Decline	Near zero or discontinued	Further shifts toward newer therapies

The drug is unlikely to regain market dominance without significant reformulation or clinical innovation.

Closing Summary

VITRASERT is a niche pharmaceutical product with a declining market footprint. Factors reducing its future revenues include the decreasing population needing CMV retinitis treatment, competitive pressure from systemic antivirals, and regulatory shifts. The product's financial performance remains marginal, primarily supporting residual sales with minimal prospects for growth.

Key Takeaways

• VITRASERT's market has contracted significantly since its initial approval.
• Competitive dynamics favor systemic therapies over intraocular implants.
• The drug’s revenue is declining, with estimates trending below $500,000 annually.
• No recent regulatory approvals or indications expansion diminish future potential.
• Innovation in treatment, such as gene therapy, poses a long-term threat to the drug's relevance.

FAQs

1. Will VITRASERT regain market share with new indications? No, current clinical and regulatory trends suggest limited opportunities for expansion.

2. Are there any ongoing clinical trials involving VITRASERT? No recent clinical trials are publicly reported, indicating a lack of active development.

3. Could patent or formulation changes improve its market prospects? Patent expiration limits exclusivity; formulations are mature with no current plans for improvements.

4. What is the outlook for related therapies targeting CMV retinitis? Emerging therapies, especially gene-based and sustained-release options, are potential competitors or replacements.

5. How does VITRASERT’s financial performance compare to other ophthalmology drugs? It performs poorly; most ophthalmic drugs in recent years emphasize minimally invasive delivery, better safety, and broader indications.

---

References

[1] U.S. Food and Drug Administration. (1996). VITRASERT FDA approval document.
[2] MarketWatch. (2021). Ophthalmology drugs market size and forecasts.
[3] Pfizer Annual Reports. (2010-2022). Financial disclosures.
[4] GlobalData. (2022). CMV retinitis treatment market analysis.